Martien van Osch

For this reason he splits his time between operational activities and the finance function. In terms of investment focus, Martien spearheads the medical device related activities at Forbion and as such was responsible for the recent exit of Pathway Medical Technologies, Inc., sold to Bayer Medrad in 2011 for USD 125 million. He currently actively contributes to the boards of Circulite, Inc., Mitralign Inc., PneumRx, Inc and Santaris Pharma AS. His experience in the life sciences industry also includes prior non-executive board positions at Cambridge Drug Discovery Ltd (sold to Biofocus Plc in 2001), Impella Cardiosystems (sold to Abiomed, Inc. in 2005), Acadia Pharmaceuticals (IPO on Nasdaq in 2004) and Flowmedica, Inc. (sold to Angiodynamics in 2009). After joining ABN AMRO as a Senior Analyst in Group Planning and Control, in 1998 Martien switched to ABN AMRO Capital and decided to join the newly formed life sciences team in 2000 as an investment director. There he developed the Medical Devices investment strategy e.g. by joining the ATI (Accelerating Technologies, Inc.) incubator initiative, focused on start-ups in Interventional Cardiology.